Docket Number:12A-1020411
Inventor:Fu-Tong Liu, Wei-Chen Hsieh, Ri-Yao Yang
IP Status:TW I516268、US patent no. US9121021B2
Abstract:
The invention demonstrates that galectin-12 regulates several key sebaceous functions, including sebocyte differentiation, proliferation and lipogenesis. In addition, the invention provides a method to inhibit expression of galectin-12 and its consequent activity in modulating sebaceous gland function. Galectin-12 inhibitors can be developed as therapeutic drugs for the treatment of acne vulgaris and sebaceous gland disorders.
Fields of Application:
It is possible to develop galectin-12 inhibitors, galectin-12 antagonists, and galectin-12 antisense oligonucleotides, etc. as therapeutic drugs for acne and other sebaceous glands diseases such as sebaceous hyperplasia, and sebaceous gland carcinoma, atopic dermatitis, seborrheic dermatitis and primary cicatricial alopecia.
Advantages when compared to the existing technologies:
Topical retinoids, oral isotretinoin, and antimicrobials have been currently used as first-line therapies for acne since they can suppress sebaceous gland activity, including reduction of sebum secretion, sebaceous lipogenesis, colocolonization of P. Acnes and its subsequent pro-inflammatory effects on comedogenesis. Unfortunately, these conventional therapies may not be effective against refractory acne. They can also lead to antibiotic resistance and serious side effects. This invention indicates that galectin-12 can modulate various key sebaceous functions and is expressed specifically in sebaceous gland, therefore indicating a great potential and a distinct advantage of developing galectin-12 inhibitors such as modified siRNAs as a therapeutic tool for the treatment of acne. It is easy to modulate the expression of galectin-12 by inhibitors without targeting other skin cells.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
